Skip to main content

Table 1 Baseline characteristic of patients in treatment and control group

From: Efficacy of the Essential Amino Acids and Keto-Analogues on the CKD progression rate in real practice in Russia - city nephrology registry data for outpatient clinic

 

Treatment group

Control group

p

Number of patients

96

96

 

Diabetes mellitus type II

12/96 (13 %)

14/96 (14 %)

p = 0.8

Polycystic kidney disease

6/96 (6 %)

8/96 (8 %)

p = 0.6

Hypertension

23 (24 %)

20 (21 %)

p = 0.6

Male/female

40/56 (42 %)

44/52 (46 %)

p = 0.6

Age

54 ± 15

57 ± 13

p = 0.14

eGFR (CKD-EPI), ml/min/1.73 m2

23 ± 9

25 ± 11

p = 0.17

CKD stage 3B/4/5

28/43/25 (29 %/45 %/26 %)

33/37/26 (34 %/39 %/27 %)

p = 0.6

Albumin, g/dl

4.1 ± 0.5

4.2 ± 0.4

p = 0.13

Calcium, mmol/l

2.28 ± 0.16

2.26 ± 0.14

p = 0.4

Phosphate, mmol/l

1,27 ± 0,26

1,21 ± 0,24

p = 0.10

Sodium, mmol/l

140 ± 3

141 ± 3

p = 0.02

Cholesterol, mmol/l

5.8 ± 1.2

5.5 ± 1.0

p = 0.06

Triglycerides, mmol/

2.06 ± 0.98

1.85 ± 1.11

p = 0.19

Hemoglobin, g/dl

12.4 ± 1.4

12.2 ± 1.3

p = 0.3

Serum Fe, μmol/l

13 ± 5

12 ± 4

p = 0.13

CRP, mg/dl

0.1 ÷ 0.6

0.2 ÷ 0.8

p = 0.13

Mean proteinuria, g/day

1.18 ÷ 2.56

1.24 ÷ 2.42

p = 0.06

Maximal proteinuria, g/day

1.49 ÷ 4.94

1.56 ÷ 5.72

p = 0.11

Number of patients with hypertension (>140/90 mmHg)

31/96 (32 %)

34/96 (35 %)

p = 0.5

Systolic blood pressure

137 ± 20

139 ± 22

p = 0.5

Diastolic blood pressure

83 ± 12

81 ± 11

p = 0.2